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Abstract
The prognostic value of proliferation index (PI) and apoptotic index (AI), caspase-8, -9 and -10 expression have been
investigated in primary Ewing’s sarcoma family of tumours (ESFT). Proliferating cells, detected by immunohistochemistry for
Ki-67, were identified in 91% (91/100) of tumours with a median PI of 14 (range 0–87). Apoptotic cells, identified using the
TUNEL assay, were detected in 96% (76/79) of ESFT; the median AI was 3 (range 0–33). Caspase-8 protein expression was
negative (0) in 14% (11/79), low (1) in 33% (26/79), medium (2) in 38% (30/79) and high (3) in 15% (12/79) of tumours,
caspase-9 expression was low (1) in 66% (39/59) and high (3) in 34% (20/59), and caspase-10 protein was low (1) in 37% (23/
62) and negative (0) in 63% (39/62) of primary ESFT. There was no apparent relationship between caspase-8, -9 and -10
expression, PI and AI. PI was predictive of relapse-free survival (RFS; p = 0.011) and overall survival (OS; p =,0.001) in a
continuous model, whereas AI did not predict outcome. Patients with tumours expressing low levels of caspase-9 protein
had a trend towards a worse RFS than patients with tumours expressing higher levels of caspase-9 protein (p = 0.054, log
rank test), although expression of caspases-8, -9 and/or -10 did not significantly predict RFS or OS. In a multivariate analysis
model that included tumour site, tumour volume, the presence of metastatic disease at diagnosis, PI and AI, PI
independently predicts OS (p = 0.003). Consistent with previous publications, patients with pelvic tumours had a
significantly worse OS than patients with tumours at other sites (p = 0.028); patients with a pelvic tumour and a PI$20 had a
6 fold-increased risk of death. These studies advocate the evaluation of PI in a risk model of outcome for patients with ESFT.
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Introduction
Ewing’s sarcoma family of tumours (ESFT) can arise in bone or
soft tissue sites at any age, but most frequently are diagnosed in
bony sites in children and young adults [1]. Five year survival rates
for patients diagnosed with localised disease are between 60 and
70%, although outcome for patients with metastasis is lower
despite multimodality treatment incorporating combination che-
motherapy, surgery and radiotherapy. Since improved patient
outcome is anticipated by adapting therapy based on risk, a
number of prognostic clinical factors have been described
including the presence of metastatic disease at the time of
diagnosis [2], tumour volume (greater than 200 ml) [3] and pelvic
primary tumours [4,5] at diagnosis in patients with localised
disease. Despite these observations there is currently no universally
accepted informative staging system in ESFT.
High proliferation index (PI), is reported to predict poor
outcome in colon carcinoma [6], renal cell carcinoma [7], cervical
carcinoma [8], neuroblastoma [9], bladder [10] and breast [11–
13] cancer, as well as ESFT [14–16]. Although apoptotic index
(AI) affects tumour viability and growth, the relationship between
AI and prognosis is controversial and has not previously been
investigated in ESFT. High AI is predictive of increased survival in
patients with osteosarcoma [17] and gastric cancer [18], and low
AI has been associated with high grade tumours of the ovary [19],
kidney [20] and colon [6]. In contrast, low AI has been associated
with a higher mean survival in childhood acute lymphoblastic
leukaemia (ALL) [21] and patients with colorectal carcinoma [22].
Since tumour growth reflects the number of both proliferating
and apoptotic cells, we have hypothesised that PI and AI may
more reliably predict outcome than PI alone. This hypothesis is
supported by studies in patients with adenocarcinoma of the
uterine cervix, where the ratio of PI/AI was predictive of survival
but not PI or AI alone [23]. The relationship between expression
of the effector caspases, PI, AI and outcome is poorly investigated,
caspase-8 being the most frequently studied. Methylation of the
CASP8 gene has been associated with low levels of caspase-8
expression, reduced response to chemotherapeutic agents and
poor outcome in a number of different cancer types including
medulloblastoma [24] and neuroblastoma [25,26], although this
remains controversial at least in neuroblastoma [27]. Lack or low
caspase-8 expression has also been reported in a number of other
cancer types including osteosarcoma [28] and squamous cell
carcinoma of the tongue [29]. In ESFT cell lines [30] and tumours
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[31], expression is variable [32,33] and is reported to have no
correlation with outcome [33].
Although caspase-9 and -10 are executors of apoptosis, little is
known of their prognostic value in primary tumours. Expression of
cleaved caspase-9 protein correlates with a longer OS in patients
with Hodgkin’s lymphoma [34], although the clinical significance
of low caspase-9 expression in colon carcinoma [35], medullo-
blastoma [24] and gastric carcinoma [36] remains unclear.
Expression of caspase-10 is also low in gastric carcinoma [36],
rectal [37] and colorectal [38] cancers. The aims of this study were
to examine PI, AI and expression of caspases-8, -9 and -10 in a
panel of primary ESFT to evaluate and compare their prognostic
power.
Materials and Methods
Clinical samples
Tumour samples were collected at diagnosis from 105 patients
with ESFT, diagnosis was confirmed by reverse transcriptase
polymerase chain reaction (RT-PCR) for the EWS-ETS gene
rearrangements in 80/105 tumours. Of the remaining 25 tumour
samples, CD99 expression was confirmed by immunohistochem-
istry (IHC) for MIC-2 in 25/25 tumours. It was not possible to
analyse all tumours for all markers due to limited amounts of
material; suitable material was available to analyse PI in 100/105,
AI in 79/105, caspase-8 in 79/105, caspase-9 in 59/105 and
caspase-10 in 62/105 of cases. The presence of metastases was
detected by conventional imaging and examination of bone
marrow aspirates by light microscopy.
Ethics statement
Ethical approval for this study was obtained from Trent Multi-
centre Research Ethics Committee (MREC 98/4/023; MREC
98/0/44). Informed written consent was obtained from all
participants.
Immunohistochemistry for Ki-67, caspases-8, -9 and -10
Immunohistochemistry and antigen retrieval were optimised
using sections (5 mm) of frozen or formalin fixed-paraffin
embedded (FF-PE) ESFT cell pellets; sections of TC-32 cell pellets
were included as positive controls in subsequent assays. Sequential
sections (5 mm) of frozen (n = 86) and FF-PE (n = 19) primary
ESFT were analysed. FF-PE sections were hydrated and antigen
retrieval was performed by boiling the sections in citric acid buffer
for 10 minutes prior to analysis. Sections processed without
primary antibody or with isotype matched antibody were included
as negative controls. All sections were counterstained with
haematoxylin and mounted in DePeX mounting medium.
Proliferating cells were detected by immunohistochemistry for
Ki-67 using a mouse monoclonal antibody (1:100; Dako,
Cambridgeshire, UK) and 3 stage peroxidase [39]. PI = [number
of Ki-67 positive cells 4 number of cells scored]6100; 100 cells
were scored in 3 different fields of view by two independent
observers.
Caspase-8 and caspase-9 proteins were detected using the
Rabbit Envision Kit (Dako) and caspase-8 (1 in 50; Santa Cruz,
Heidelberg, Germany) or caspase-9 (1 in 100; Abcam, Cambridge,
UK) antibodies. Prior to incubation with primary antibody
overnight at 4uC, sections were incubated with normal goat
serum (1 in 10; Dako) for 1 hour at room temperature, wash steps
were performed with TBS plus 1% Tween 20. Caspase-10 protein
was detected using caspase-10 primary antibody (1 in 150; Santa
Cruz) and the Goat Vectastain ABC kit (Vector Laboratories,
Peterborough, UK); sections were incubated with primary
antibody for one hour at 37uC and antibody was visualised using
DAB+ substrate (Dako).
Identification of apoptotic cells by terminal
deoxynucleotidyl transferase (TdT) mediated dUTP nick-
end labelling (TUNEL)
Apoptotic cells were detected by TUNEL using the ApopTag
Peroxidase In Situ Apoptosis Detection Kit (Millipore, UK),
according to manufacturer’s instructions. AI= [number of TU-
NEL positive cells 4 number of cells scored]6100; 100 cells were
scored in three different fields of view by two independent
observers.
Scoring of immunohistochemistry
Sections were visualised by light microscopy (Zeiss Axioplan
microscope, Zeiss, UK) and scored using the following criteria.
Caspase-8 expression was negative (0), low (1), medium (2) or high
(3) based on intensity of staining compared to a caspase-8 positive
(2, tumour 11) and negative (0, tumour 45) tissue. Caspase-9
expression was scored as negative (0), low (1), medium (2) or high
(3) dependant on staining intensity compared to tissue with high (3,
tumour 55) or low (1, tumour 57) expression, and caspase-10 as
negative (0), low (1), medium (2) or high (3) compared to a caspase-
10 expressing tumour (1, tumour 1) and a negative (0, tumour 57).
Staining was independently evaluated by two observers.
Statistical analysis
All statistical analyses were carried out using SAS v9.2 (SAS
Institute Inc., Cary, NC, USA). RFS was calculated from the date
of diagnosis to relapse or death, or the date of last assessment
without event. OS was defined as the time from diagnosis to death
or the date last seen alive. Univariate analyses explored whether a
number of covariate factors predict prognosis: age group (,14, $
14) [40]; tumour site (pelvic, other) [4]; tumour volume (,200 ml,
$200 ml) [3]; metastases at diagnosis (any, none) [2]; response to
treatment (,90%, $90%) [41]; PI (as a continuous variable); AI
(as a continuous variable); caspases-8, -9 and -10 (0/1, 2/3). RFS
and OS curves were calculated using the Kaplan-Meier method by
each covariate group, and the results for each compared using the
log rank test. Caution was taken in statistical interpretation to
minimise the effect of multiplicity, and the p-values were
compared to 0.01 in order to control the type 1 error rate.
Cox proportional hazards regression was carried out on OS,
incorporating the most significant covariates to assess which are
prognostic in a multivariate setting. A stepwise procedure was
used, with significance level for entering an explanatory variable
into the model set to 0.05 and significance level for removing an
explanatory variable from the model set to 0.1.
An investigation was carried out into the optimal cut-point
choice for PI. PI was investigated as a continuous covariate within
a Cox model; the log-rank value was calculated over the whole
range of cut-points to visualise any patterns, and the cut-point log
rank values were compared to those when the data is described as
a continuous covariate. Fractional polynomials were calculated to
investigate how the data could best be described as a continuous
covariate, using a series of predefined transformations of predictor
variables [42]. If the cut-point describes the data significantly
better than a fitted model, it is likely that the cut-point effect is real;
otherwise the survival may be related to the PI on a continuous
scale.
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Results
Frozen and FF-PE tumour distribution with age at diagnosis,
tumour site and PI confirmed that frozen and FF-PE tumours
could be considered as a single sample set (Table S1). Patient and
tumour details, PI, AI and protein expression profiles are
summarised in Table S2.
Prognostic power of clinical parameters
The prognostic power of parameters previously reported to be
of clinical value was investigated in this patient cohort. Consistent
with previous studies a tumour volume $200 ml was predictive of
a poor OS and RFS (p= 0.019 and 0.013 respectively, log rank
test, Figure 1A) compared to a tumour volume ,200 ml.
Furthermore, patients with pelvic tumours had a worse OS and
RFS (p= 0.019 and 0.009 respectively, log rank test, Figure 1B)
than patients with tumours presenting in other sites. Age of the
patient (,14 years compared to $14 years) and response to
treatment (,90% necrosis of tumour post-treatment compared to
$90% necrosis) did not predict outcome in this cohort. The
presence of metastatic disease at diagnosis detected by conven-
tional imaging and examination of bone marrow aspirates by light
microscopy for tumour cells did not predict outcome, although
there was a non-significant trend towards patients with metastasis
at diagnosis having a worse OS (p = 0.099, log rank test). Site of
metastasis was available for 20/32 (63%) patients with metastasis;
patients with bone metastasis at diagnosis had a significantly worse
OS and RFS (p =,0.001 and ,0.001 respectively, log rank test)
than patients with no metastatic disease or metastasis at other sites.
Proliferation and apoptosis in primary ESFT
Proliferating cells were identified in 91% (91/100) of tumours
with a median PI of 14 (range= 0–87) (Figure 2A; Table S2).
Fractional polynomial analysis showed that none of the transfor-
mations were significantly better than the simple linear model,
suggesting that PI is linearly related to OS. The log-rank values
over the entire range of cut-points show that there is no optimal
cut-point, and since the log-rank values were not substantially
Figure 1. A. Kaplan Meier survival plots comparing the overall and relapse-free survival of patients with a tumour volume$200 ml
with that of patients with a tumour volume ,200 ml, p=0.019 and 0.0133 respectively; log rank test. Crosses indicate censored
events. B. Kaplan Meier survival plots to compare the overall and relapse-free survival of patients with pelvic tumours to that of patients with
tumours at other sites, p = 0.0185 and 0.0088 respectively; log rank test. Crosses indicate censored events.
doi:10.1371/journal.pone.0104106.g001
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higher than those for the linear model supports the conclusion that
PI is a truly continuous variable.
A Cox regression for OS incorporating PI as a continuous
covariate demonstrates that those patients with tumours that have
a high PI at diagnosis will have a worse OS than those patients
with a lower PI (x2 = 11.5, p,0.001, HR=1.04, 95% CI= 1.02–
1.06). PI was also included in a multivariate analysis for OS along
with the covariates tumour site, tumour volume, metastases at
diagnosis and AI. In this analysis PI remained strongly significant
(x2 = 9.11, p = 0.003, HR=1.04, 95% CI= 1.01–1.06), along with
tumour site (x2 = 4.85, p = 0.028, HR=2.81, 95% CI= 1.12–
7.04), where patients with pelvic tumours had a worse outcome.
With these two variables in the model, none of the other factors
significantly added to the prediction of OS. Patients with a pelvic
tumour and a high PI have a worse OS than those with either
factor alone; patients with a pelvic tumour and a PI$20 have a
HR of 5.8. A Cox regression for RFS incorporating PI as a
continuous covariate demonstrates that those patients with
tumours that have a high PI at diagnosis will have a worse RFS
than those patients with a lower PI (x2 = 6.5, p = 0.011,
HR=1.03, 95% CI= 1.01–1.06). Apoptotic cells were identified
in 96% (76/79) of ESFT with a median AI of 3 (range= 0–33)
(Figure 2B; Table S2); AI does not predict OS (p = 0.137, Cox
regression) or RFS (p = 0.596, Cox regression).
Caspase-8, -9 and -10 protein expression in primary ESFT
Caspase-8 protein was heterogeneously expressed in the
cytoplasm (Figure 3A; Table S2); negative (0) in 11/79 (14%),
low (1) in 26/79 (33%), medium (2) in 30/79 (38%) and high (3) in
12/79 (15%) primary ESFT. Caspase-8 protein expression did not
predict OS or RFS (p = 0.250 and 0.235 respectively, log rank
test). Caspase-10 protein was expressed at a low level (1) in the
cytoplasm of 23/62 (37%) of tumours and not expressed (0) in 39/
62 (63%; Figure 3B; Table S2) and did not predict OS (p = 0.732,
log rank test) or RFS (p = 0.693, log rank test).
Caspase-9 protein was detected in the cytoplasm and nucleus of
ESFT (Figure 3C; Table S2), expression was low (1) in 39/59
(66%) and high (3) in 20/59 (34%) of tumours. Expression of
caspase-9 was not predictive of OS (p = 0.275, log rank test),
however, patients with tumours expressing low levels of caspase-9
protein had a strong trend towards a worse RFS than patients with
tumours expressing high levels of caspase-9 protein (p = 0.054, log
rank test, Figure S1). Nuclear or cytoplasmic expression did not
appear to contribute to the prognostic value of low and high
expression across the tumour. This is worthy of investigation in a
validation tumour cohort.
Discussion
In this study we demonstrate for the first time that high numbers
of proliferating cells in primary ESFT are predictive of a worse
RFS and OS in a continuous model. In a multivariate analysis,
high PI was predictive of poor OS independent of tumour site,
tumour volume, metastasis at diagnosis or AI. The prognostic
value of PI is consistent with results from univariate [14,16] and
multivariate [15] discontinuous studies in ESFT. However there is
considerable variation in the level above which a tumour is scored
as having a high number of proliferating cells; in the published
literature high PI has being defined as $50% [16] or .5% [15].
This wide discrepancy can be explained by the variable having a
truly continuous distribution. One group has reported no
association between PI and outcome using an arbitrary cut-point
of 20 (based on the literature at the time, p = 0.71) or a statistically
defined cut-point of 8.3 (generated by analysis of the ROC curve,
p = 0.06) [14]; this most likely reflects the continuous relationship
between PI and outcome and the distribution of patients in this
small group (n= 37). We have detected proliferating cells in 91%
of ESFT, higher than previous studies where they reported Ki-67
staining in 57% [14] and 34% [15]. This is likely to be due to the
fact that these authors only reported Ki-67 expression once the PI
had reached the cut points of 8.3% and 5% respectively, whereas
we have reported tumours to be positive with a PI of 1% or
greater. Since a higher PI is predictive of worse OS in a
continuous model, patient risk should optimally be defined by
incorporating the PI value rather than an arbitrary cut-point into a
predictive model. Alternatively the introduction of PI as a
biomarker of risk into the clinic may be enabled by defining a
cut-point that identifies patients at ultra-high risk, for whom
current treatment offers no benefit and might be offered novel
investigational treatments. For example, we have identified that
patients with a PI value of$20 (33% of patients in this study) have
a two-fold increased risk of death (HR=2.0) or relapse (HR=1.9),
whereas patients with a pelvic tumour and a PI$20 have a 6 fold-
increased risk of death (HR=5.8) suggesting PI and tumour site
should be included in a risk model for patients with ESFT. The
quantification of PI by immunohistochemistry for Ki-67 protein is
a robust reproducible assay that can be performed reliably on
paraffin embedded tumour at low cost, and so may readily be
introduced into pathology practice. The utility of this marker, and
others where quantification is important, may benefit from an
observer independent assessment using digital imaging to allow
high-throughput analysis and to overcome subjectivity and
heterogeneity of expression. A recent study found that Ki-67
Figure 2. A. Immunohistochemistry for Ki-67 performed on
primary ESFT (5 mm). Ki-67 protein was visualised with the DAB
substrate, proliferating cells are identified by Ki-67 positive nuclei (see
arrows). Immunohistochemistry performed in the absence of primary
antibody was included to control for non-specific binding of the
secondary antibody (No primary AB). Magnification6400. B. TUNEL on
primary ESFT (5 mm). Apoptotic cells were identified by TUNEL positive
nuclei (see arrows). The TUNEL assay was performed in the absence TdT
enzyme to control for non-specific staining (No enzyme). Magnification
6400.
doi:10.1371/journal.pone.0104106.g002
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quantification by digital image analysis and manual counting were
highly concordant [43]. It is now important to evaluate the
prognostic value of PI as a continuous variable with other
prognostic biomarkers to identify the most clinically informative
algorithm of risk for patients with ESFT.
The number of apoptotic cells was low in the majority of
primary ESFT, and AI did not predict prognosis in the univariate
or multivariate models. This is the first study to describe this
relationship in ESFT. AI has been correlated with survival in other
cancers with contradictory findings, however analysis has been
based values above and below cut points rather than as a
continuous variable [17–19]. An increase in AI in tumours post-
treatment may be a useful surrogate tumour marker of response to
chemotherapy. For example, AI has been shown to correlate with
pathological response in breast cancer biopsies collected after
therapy [44,45]. Some studies have suggested that immunohisto-
chemistry for cleaved caspase-3 might replace measures of
apoptosis such as TUNEL [46,47], and absence or low numbers
of cleaved caspase-3 positive cells have been associated with a
worse prognosis in patients with nasopharyngeal carcinoma [48]
and glioma [49]. However the transient expression of cleaved
caspases and homology between the cleavage sites [50] may limit
the clinical utility of IHC for cleaved caspases as predictive
biomarkers. In contrast we have examined the hypothesis that
expression of full-length caspases-8, -9 and -10 may be surrogate
markers of tumour apoptotic potential, response to treatment and
outcome. We have found considerable heterogeneity in the
expression of these effectors of cell death, with no correlation
between expression of the different caspases. Expression of caspase
8 and 10 was not significantly associated with OS or RFS. There
was however a non-significant trend towards patients with
tumours expressing low levels of caspase-9 protein having a worse
RFS, which may reflect the importance of caspase-9 as an effector
molecule of apoptotic cell death following treatment with current
therapeutics. Low levels of caspase-9 protein in primary tumour
could therefore identify patients that are most likely to benefit from
non-caspase-9 dependent treatments, such as death receptor (DR)-
mediated apoptosis through caspase-8 cleavage and induction of
the non-mitochondrial apoptotic pathway [51,52]. Consistent with
this hypothesis ESFT are reported to be sensitive to TRAIL-
induced apoptosis in preclinical models of ESFT growth [53–55].
Heterogeneous expression was not explained by differential
methylation of the CASP8 or CASP9 gene promoters (Figure
S2; [56]).
This study highlights the value of PI as a predictive biomarker of
RFS and OS in patients with ESFT when measured in primary
tumour. PI remained predictive of OS in a multivariate analysis,
indicating that PI provides additional prognostic information
independent of clinical markers used in current practice. This
observation was authentic in a continuous statistical model,
demonstrating that survival worsens as PI increases and therefore
that risk can be defined most accurately based on PI as a
continuous measure rather than choosing an arbitrary cut-point.
The introduction of this assay into the pathological examination of
ESFT at diagnosis may improve the ability to identify those
patients destined to do badly that might benefit from alternative
investigational treatment.
Supporting Information
Figure S1 Kaplan Meier survival plot to compare the
relapse-free survival of patients with tumours that had
low caspase-9 expression to that of patients with
tumours that had high caspase-9 expression,
p=0.0538; log rank test. Crosses identify censored events.
(TIF)
Figure S2 Methylation of the CASP9 promoter in ESFT.
PCR products in lanes labelled U and M indicate the presence of
unmethylated and methylated CASP9 promoter regions respec-
tively. DNA extracted from peripheral blood (PB) from healthy
volunteers was included as an unmethylated control and CpG
Methylase treated peripheral blood DNA (Meth PB) was used as a
methylation control.
(PDF)
Table S1 Comparison between frozen and FF-PE tu-
mours and their distribution by age at diagnosis,
tumour site and PI.
(DOC)
Table S2 Summary of patient and tumour information,
PI, AI and protein expression. Details of the 105 ESFT
samples analysed with clinical information, PI and AI and
expression of caspases-8, -9 and -10.
(XLS)
Acknowledgments
Thank you to Andrea Berry (AB) and Dr Catherine Cullinane (Paediatric
Pathology, SJUH) for help scoring immunohistochemistry. Thanks also to
Mr R Grimer, Royal Orthopaedic Hospital, Birmingham and the CCLG
Tumour Bank and Data Centre for providing tumour samples and clinical
outcome data.
Author Contributions
Conceived and designed the experiments: S.Burchill. Performed the
experiments: S.Brownhill. Analyzed the data: S.Brownhill DC S.Burchill.
Contributed reagents/materials/analysis tools: S.Burchill. Wrote the
paper: S.Brownhill DC S.Burchill. Developed the study concept, secured
grant funding: S.Burchill. Contributed to the interpretation and opinions
expressed in this manuscript, and approved the final version of the
manuscript: S.Brownhill DC S.Burchill.
References
1. Burchill SA (2003) Ewing’s sarcoma: diagnostic, prognostic, and therapeutic
implications of molecular abnormalities. Journal of clinical pathology 56: 96–
102.
2. Terrier P, Llombart-Bosch A, Contesso G (1996) Small round blue cell tumors in
bone: prognostic factors correlated to Ewing’s sarcoma and neuroectodermal
tumors. Semin Diagn Pathol 13: 250–257.
3. Ahrens S, Hoffmann C, Jabar S, Braun-Munzinger G, Paulussen M, et al. (1999)
Evaluation of prognostic factors in a tumor volume-adapted treatment strategy
for localized Ewing sarcoma of bone: the CESS 86 experience. Cooperative
Ewing Sarcoma Study. Med Pediatr Oncol 32: 186–195.
4. Craft AW, Cotterill SJ, Bullimore JA, Pearson D (1997) Long-term results from
the first UKCCSG Ewing’s Tumour Study (ET-1). United Kingdom Children’s
Figure 3. Immunohistochemistry on primary ESFT (5 mm) for caspases-8, -9 and -10. Immunohistochemistry in the absence of primary
antibody was to control for non-specific binding of the secondary antibody (No primary AB). Magnification of images=6400. Caspase expression was
scored as negative (0), low (1), medium (2) or high (3). A. Caspase-8 protein expression. B. Caspase-10 protein expression. C. Caspase-9 protein
expression.
doi:10.1371/journal.pone.0104106.g003
Proliferation Index Predicts Prognosis in ESFT
PLOS ONE | www.plosone.org 6 August 2014 | Volume 9 | Issue 8 | e104106
Cancer Study Group (UKCCSG) and the Medical Research Council Bone
Sarcoma Working Party. Eur J Cancer 33: 1061–1069.
5. Nesbit ME, Jr., Gehan EA, Burgert EO, Jr., Vietti TJ, Cangir A, et al. (1990)
Multimodal therapy for the management of primary, nonmetastatic Ewing’s
sarcoma of bone: a long-term follow-up of the First Intergroup study. J Clin
Oncol 8: 1664–1674.
6. Sinicrope FA, Hart J, Hsu HA, Lemoine M, Michelassi F, et al. (1999) Apoptotic
and mitotic indices predict survival rates in lymph node-negative colon
carcinomas. Clin Cancer Res 5: 1793–1804.
7. Rioux-Leclercq N, Turlin B, Bansard J, Patard J, Manunta A, et al. (2000) Value
of immunohistochemical Ki-67 and p53 determinations as predictive factors of
outcome in renal cell carcinoma. Urology 55: 501–505.
8. Gasinska A, Urbanski K, Gruchala A, Biesaga B, Kojs Z (2002) A ratio of
apoptosis to mitosis, proliferation pattern and prediction of radiotherapy
response in cervical carcinoma. Neoplasma 49: 379–386.
9. Mejia C, Navarro S, Pellin A, Ruiz A, Castel V, et al. (2003) Prognostic
significance of cell proliferation in human neuroblastoma: comparison with
other prognostic factors. Oncol Rep 10: 243–247.
10. Lopez-Beltran A, Luque RJ, Alvarez-Kindelan J, Quintero A, Merlo F, et al.
(2004) Prognostic factors in stage T1 grade 3 bladder cancer survival: the role of
G1-S modulators (p53, p21Waf1, p27kip1, Cyclin D1, and Cyclin D3) and
proliferation index (ki67-MIB1). Eur Urol 45: 606–612.
11. Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, et al. (2012) A Ki67/
BCL2 index based on immunohistochemistry is highly prognostic in ER-positive
breast cancer. The Journal of pathology 226: 97–107.
12. Ibrahim T, Farolfi A, Scarpi E, Mercatali L, Medri L, et al. (2012) Hormonal
Receptor, Human Epidermal Growth Factor Receptor-2, and Ki67 Discordance
between Primary Breast Cancer and Paired Metastases: Clinical Impact.
Oncology 84: 150–157.
13. van Diest PJ, van der Wall E, Baak JP (2004) Prognostic value of proliferation in
invasive breast cancer: a review. J Clin Pathol 57: 675–681.
14. Amir G, Issakov J, Meller I, Sucher E, Peyser A, et al. (2002) Expression of p53
gene product and cell proliferation marker Ki-67 in Ewing’s sarcoma:
correlation with clinical outcome. Hum Pathol 33: 170–174.
15. Lopez-Guerrero JA, Machado I, Scotlandi K, Noguera R, Pellin A, et al. (2011)
Clinicopathological significance of cell cycle regulation markers in a large series
of genetically confirmed Ewing’s sarcoma family of tumors. International journal
of cancer Journal international du cancer 128: 1139–1150.
16. Sollazzo MR, Benassi MS, Magagnoli G, Gamberi G, Molendini L, et al. (1999)
Increased c-myc oncogene expression in Ewing’s sarcoma: correlation with Ki67
proliferation index. Tumori 85: 167–173.
17. Wu X, Cai ZD, Lou LM, Zhu YB (2012) Expressions of p53, c-MYC, BCL-2
and apoptotic index in human osteosarcoma and their correlations with
prognosis of patients. Cancer epidemiology 36: 212–216.
18. Jia Y, Dong B, Tang L, Liu Y, Du H, et al. (2012) Apoptosis index correlates
with chemotherapy efficacy and predicts the survival of patients with gastric
cancer. Tumour biology : the journal of the International Society for
Oncodevelopmental Biology and Medicine 33: 1151–1158.
19. Yamasaki F, Tokunaga O, Sugimori H (1997) Apoptotic index in ovarian
carcinoma: correlation with clinicopathologic factors and prognosis. Gynecol
Oncol 66: 439–448.
20. Tannapfel A, Hahn HA, Katalinic A, Fietkau RJ, Kuhn R, et al. (1997)
Incidence of apoptosis, cell proliferation and P53 expression in renal cell
carcinomas. Anticancer Res 17: 1155–1162.
21. Stammler G, Sauerbrey A, Zintl F, Volm M (1997) Apoptotic index, Fas and
bcl-2 in initial and relapsed childhood acute lymphoblastic leukaemia. Apoptosis
2: 377–383.
22. Bendardaf R, Ristamaki R, Kujari H, Laine J, Lamlum H, et al. (2003)
Apoptotic index and bcl-2 expression as prognostic factors in colorectal
carcinoma. Oncology 64: 435–442.
23. Leung TW, Xue WC, Cheung AN, Khoo US, Ngan HY (2004) Proliferation to
apoptosis ratio as a prognostic marker in adenocarcinoma of uterine cervix.
Gynecol Oncol 92: 866–872.
24. Pingoud-Meier C, Lang D, Janss AJ, Rorke LB, Phillips PC, et al. (2003) Loss of
caspase-8 protein expression correlates with unfavorable survival outcome in
childhood medulloblastoma. Clin Cancer Res 9: 6401–6409.
25. Teitz T, Wei T, Valentine MB, Vanin EF, Grenet J, et al. (2000) Caspase 8 is
deleted or silenced preferentially in childhood neuroblastomas with amplification
of MYCN. Nat Med 6: 529–535.
26. Yang Q, Kiernan CM, Tian Y, Salwen HR, Chlenski A, et al. (2007)
Methylation of CASP8, DCR2, and HIN-1 in neuroblastoma is associated with
poor outcome. Clin Cancer Res 13: 3191–3197.
27. Fulda S, Poremba C, Berwanger B, Hacker S, Eilers M, et al. (2006) Loss of
caspase-8 expression does not correlate with MYCN amplification, aggressive
disease, or prognosis in neuroblastoma. Cancer Res 66: 10016–10023.
28. Kaseta MK, Gomatos IP, Khaldi L, Tzagarakis GP, Alevizos L, et al. (2007)
Prognostic value of bax, cytochrome C, and caspase-8 protein expression in
primary osteosarcoma. Hybridoma (Larchmt) 26: 355–362.
29. Andressakis D, Lazaris AC, Tsiambas E, Kavantzas N, Rapidis A, et al. (2008)
Evaluation of caspase-3 and caspase-8 deregulation in tongue squamous cell
carcinoma, based on immunohistochemistry and computerised image analysis.
J Laryngol Otol 122: 1213–1218.
30. Takita J, Yang HW, Bessho F, Hanada R, Yamamoto K, et al. (2000) Absent or
reduced expression of the caspase 8 gene occurs frequently in neuroblastoma,
but not commonly in Ewing sarcoma or rhabdomyosarcoma. Med Pediatr
Oncol 35: 541–543.
31. Harada K, Toyooka S, Shivapurkar N, Maitra A, Reddy JL, et al. (2002)
Deregulation of caspase 8 and 10 expression in pediatric tumors and cell lines.
Cancer Res 62: 5897–5901.
32. de Hooge AS, Berghuis D, Santos SJ, Mooiman E, Romeo S, et al. (2007)
Expression of cellular FLICE inhibitory protein, caspase-8, and protease
inhibitor-9 in Ewing sarcoma and implications for susceptibility to cytotoxic
pathways. Clin Cancer Res 13: 206–214.
33. Lissat A, Vraetz T, Tsokos M, Klein R, Braun M, et al. (2007) Interferon-
gamma sensitizes resistant Ewing’s sarcoma cells to tumor necrosis factor
apoptosis-inducing ligand-induced apoptosis by up-regulation of caspase-8
without altering chemosensitivity. Am J Pathol 170: 1917–1930.
34. Santon A, Garcia-Cosio M, Cristobal E, Pascual A, Muriel A, et al. (2011)
Expression of heat shock proteins in classical Hodgkin lymphoma: correlation
with apoptotic pathways and prognostic significance. Histopathology 58: 1072–
1080.
35. Strater J, Herter I, Merkel G, Hinz U, Weitz J, et al. (2010) Expression and
prognostic significance of APAF-1, caspase-8 and caspase-9 in stage II/III colon
carcinoma: caspase-8 and caspase-9 is associated with poor prognosis.
Int J Cancer 127: 873–880.
36. Liu LX, Liu ZH, Jiang HC, Qu X, Zhang WH, et al. (2002) Profiling of
differentially expressed genes in human gastric carcinoma by cDNA expression
array. World J Gastroenterol 8: 580–585.
37. Xu B, Zhou ZG, Li Y, Wang L, Yang L, et al. (2008) Clinicopathological
significance of caspase-8 and caspase-10 expression in rectal cancer. Oncology
74: 229–236.
38. Shen XG, Wang C, Li Y, Zhou B, Xu B, et al. (2011) Downregulation of
caspase-10 predicting poor survival after resection of stage II colorectal cancer.
International journal of colorectal disease 26: 1519–1524.
39. Dalal S, Berry AM, Cullinane CJ, Mangham DC, Grimer R, et al. (2005)
Vascular endothelial growth factor: a therapeutic target for tumors of the
Ewing’s sarcoma family. Clinical cancer research : an official journal of the
American Association for Cancer Research 11: 2364–2378.
40. Rosito P, Mancini AF, Rondelli R, Abate ME, Pession A, et al. (1999) Italian
Cooperative Study for the treatment of children and young adults with localized
Ewing sarcoma of bone: a preliminary report of 6 years of experience. Cancer
86: 421–428.
41. Bacci G, Ferrari S, Bertoni F, Rimondini S, Longhi A, et al. (2000) Prognostic
factors in nonmetastatic Ewing’s sarcoma of bone treated with adjuvant
chemotherapy: analysis of 359 patients at the Istituto Ortopedico Rizzoli. J Clin
Oncol 18: 4–11.
42. Royston P, Sauerbrei W (2004) A new approach to modelling interactions
between treatment and continuous covariates in clinical trials by using fractional
polynomials. Statistics in medicine 23: 2509–2525.
43. Tang LH, Gonen M, Hedvat C, Modlin IM, Klimstra DS (2012) Objective
quantification of the Ki67 proliferative index in neuroendocrine tumors of the
gastroenteropancreatic system: a comparison of digital image analysis with
manual methods. The American journal of surgical pathology 36: 1761–1770.
44. Davis DW, Buchholz TA, Hess KR, Sahin AA, Valero V, et al. (2003)
Automated quantification of apoptosis after neoadjuvant chemotherapy for
breast cancer: early assessment predicts clinical response. Clin Cancer Res 9:
955–960.
45. Stearns V, Singh B, Tsangaris T, Crawford JG, Novielli A, et al. (2003) A
prospective randomized pilot study to evaluate predictors of response in serial
core biopsies to single agent neoadjuvant doxorubicin or paclitaxel for patients
with locally advanced breast cancer. Clin Cancer Res 9: 124–133.
46. Duan WR, Garner DS, Williams SD, Funckes-Shippy CL, Spath IS, et al. (2003)
Comparison of immunohistochemistry for activated caspase-3 and cleaved
cytokeratin 18 with the TUNEL method for quantification of apoptosis in
histological sections of PC-3 subcutaneous xenografts. J Pathol 199: 221–228.
47. Gown AM, Willingham MC (2002) Improved detection of apoptotic cells in
archival paraffin sections: immunohistochemistry using antibodies to cleaved
caspase 3. J Histochem Cytochem 50: 449–454.
48. Oudejans JJ, Harijadi A, Cillessen SA, Busson P, Tan IB, et al. (2005) Absence of
caspase 3 activation in neoplastic cells of nasopharyngeal carcinoma biopsies
predicts rapid fatal outcome. Mod Pathol 18: 877–885.
49. Kobayashi T, Masumoto J, Tada T, Nomiyama T, Hongo K, et al. (2007)
Prognostic significance of the immunohistochemical staining of cleaved caspase-
3, an activated form of caspase-3, in gliomas. Clin Cancer Res 13: 3868–3874.
50. McStay GP, Salvesen GS, Green DR (2008) Overlapping cleavage motif
selectivity of caspases: implications for analysis of apoptotic pathways. Cell
Death Differ 15: 322–331.
51. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-apoptotic
receptor agonists. Nat Rev Drug Discov 7: 1001–1012.
52. Debatin KM, Krammer PH (2004) Death receptors in chemotherapy and
cancer. Oncogene 23: 2950–2966.
53. Van Valen F, Fulda S, Truckenbrod B, Eckervogt V, Sonnemann J, et al. (2000)
Apoptotic responsiveness of the Ewing’s sarcoma family of tumours to tumour
necrosis factor-related apoptosis-inducing ligand (TRAIL). International journal
of cancer Journal international du cancer 88: 252–259.
54. van Valen F, Harrer H, Hotfilder M, Dirksen U, Pap T, et al. (2012) A Novel
Role of IGF1 in Apo2L/TRAIL-Mediated Apoptosis of Ewing Tumor Cells.
Sarcoma 2012: 782970.
Proliferation Index Predicts Prognosis in ESFT
PLOS ONE | www.plosone.org 7 August 2014 | Volume 9 | Issue 8 | e104106
55. White DE, Burchill SA (2010) Fenretinide-dependent upregulation of death
receptors through ASK1 and p38alpha enhances death receptor ligand-induced
cell death in Ewing’s sarcoma family of tumours. Br J Cancer.
56. Martinez R, Setien F, Voelter C, Casado S, Quesada MP, et al. (2007) CpG
island promoter hypermethylation of the pro-apoptotic gene caspase-8 is a
common hallmark of relapsed glioblastoma multiforme. Carcinogenesis 28:
1264–1268.
Proliferation Index Predicts Prognosis in ESFT
PLOS ONE | www.plosone.org 8 August 2014 | Volume 9 | Issue 8 | e104106
